Immigran to extend its indication to menstrual migraine.

Published: 2004-11-29 06:57:00

Updated: 2004-11-29 06:57:00

Yuyu has obtained the KFDA approval on Immigran for the treatment of menstrual associated migraine (MAM) in addition to the existing indication of "an early relief of migraine pain with or without prodromes". The MAM commonly occurs in women before and after the menstrual period.

The MAM pati...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK